Red Cat Holdings heads into the final stretch of August with one of the more contradictory setups in small-cap defense: the lending pool is completely exhausted, yet short sellers have been steadily covering for a month.
The most striking data point in the borrow market is that availability has been at zero — every share in the lending pool is currently lent out. That's not a new development; availability has been at or near zero almost every day since early July. With short interest running at 25.7% of free float on 30.7 million shares, the borrow has been fully consumed for weeks. Yet cost to borrow tells a different story: at 1.53%, it has actually fallen 23% over the past week and sits near the low end of its 30-day range. When availability is this tight but borrowing costs remain subdued, it typically reflects a market where shorts are not scrambling to add — they're managing existing positions rather than building new ones. That reading is reinforced by the direction of short interest itself, which has declined roughly 10% over the past month, from around 33.9 million shares to 30.7 million. The covering has been gradual and steady, not a panic unwind.
Options positioning adds little pressure to that picture. The put/call ratio at 0.32 is almost exactly in line with its 20-day average of 0.32, producing a z-score close to flat. Call-side interest continues to dominate — the PCR has been drifting down from around 0.37 in late July — which suggests that options traders are leaning speculative rather than defensive. The 52-week low on PCR is 0.25, so the current level is not extreme, but it does underline that hedging demand is absent despite a week that saw the stock fall 13.6% to $9.62.
The Street is uniformly bullish in direction but recently trimming in conviction. Following the latest earnings print on August 6, Needham cut its target from $20 to $15 while keeping a Buy. HC Wainwright held firm at $20. The consensus mean target is $18.33 — nearly double the current price — which signals either that analysts see a sharp dislocation or that targets haven't fully adjusted to the new post-earnings reality. The bull case centers on RCAT's Black Hawk and FANG drone programs, DoD procurement tailwinds, and NATO partnerships that could accelerate international revenue. Bears push back on persistent losses: the EV/EBITDA multiple is deeply negative at -16.5, the price-to-book is 4.2 on a loss-making business, and management has yet to demonstrate that manufacturing scale improvements will close the profitability gap. On ORTEX factor scores, the EPS momentum readings are exceptional — 98th percentile on 30-day and 95th on 90-day — but the short score rank at 3rd percentile reflects how heavily shorted the stock remains relative to peers.
Insider activity over the past month adds a note of caution. CEO and founder Jeffrey Thompson sold 150,000 shares on August 17 at $10.45, a transaction valued at $1.57 million — his second block sale in five weeks after a $1.28 million disposal in mid-July. Two independent directors also sold in August. Taken together, insiders have been net sellers of roughly $5.5 million in value over the past 90 days. That doesn't preclude the bull thesis, but it does suggest that those closest to the company have been using the stock's recovery off its June lows as an opportunity to reduce exposure.
Institutional flows tell the other side: State Street added nearly 4.9 million shares and Hood River Capital Management built a 10.6 million-share position in recent filings, becoming one of the largest holders. That kind of active-manager accumulation alongside passive-flow additions from BlackRock and Vanguard provides a meaningful counterweight to the insider selling narrative. The recent earnings print — up 6.4% on the day and 18.1% over the following five days — showed the stock can move sharply on positive catalysts. The next earnings event is scheduled for November 6, and with availability locked at zero, any meaningful short covering into that window would need to come from buyers in the open market.
What to watch: whether the steady pace of short covering continues as availability stays exhausted, and whether Needham's post-earnings target reduction triggers further analyst recalibration ahead of the November print.
See the live data behind this article on ORTEX.
Open RCAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
